The acute contractile function of the heart is controlled by the eects of released nonepinephrine (NE) on cardiac adrenergic receptors. NE can also act in a more chronic fashion to induce cardiomyocyte growth, characterized by cell enlargement (hypertrophy), increased protein synthesis, alterations in gene expression and addition of sarcomeres. These responses enhance cardiomyocyte contractile function and thus allow the heart to compensate for increased stress. The hypertrophic eects of NE are mediated through Gq-coupled a 1 -adrenergic receptors and are mimicked by the actions of other neurohormones (endothelin, prostaglandin F 2a angiotensin II) that also act on Gq-coupled receptors. Activation of phospholipase C by Gq is necessary for these responses, and protein kinase C and MAP kinases have also been implicated. Gq stimulated cardiac hypertrophy is also evident in transgenic mouse models. In contrast, stimulation of G s -coupled b-adrenergic receptors or G i -coupled receptors do not directly eect cardiomyocyte hypertrophy. Apoptosis is also induced by G-protein-coupled receptor stimulation in cardiomyocytes. Sustained or excessive activation of either Gq-or Gs-signaling pathways results in apoptotic loss of cardiomyocytes both in vitro and in vivo. Apoptosis is associated with decreased ventricular function in the failing heart. Cardiomyocytes provide an ideal model system for understanding the basis for G-protein mediated hypertrophy and apoptosis, and the mechanisms responsible for the transition from compensatory to deleterious levels of signaling. This information may prove critical for designing interventions that prevent the pathophysiological consequences of heart failure. Oncogene (2001) 20, 1626 ± 1634.
Introduction
Cardiomyocytes comprise 70 ± 80% of the mass of the adult heart. These cells are terminally dierentiated and precisely designed to rapidly alter their ionic and contractile function in response to adrenergic (sympathetic) and cholinergic (parasympathetic) input. Cardiac tumors are extremely rare and there is limited evidence for proliferation of adult cardiomyocytes. In light of these considerations, it is not immediately obvious that cardiomyocyte growth and cardiomyocyte death would be responses critical to the normal function of the heart. In fact, the ability of cardiomyocytes to undergo hypertrophic growth, which includes an increase in cell size, is an important adaptive response to a wide range of conditions that require the heart to work more eectively. As described below, adaptive or compensatory cardiomyocyte hypertrophy appears to be regulated in large part through stimulation of G-protein coupled receptors (GPCRs). Often, the ability of cardiomyocytes to function at high capacity under increased workload cannot be sustained and the heart transitions into a condition in which ventricular failure develops. One event associated with and suspected to be causally related to this transition to heart failure is the apoptotic death of cardiomyocytes. An intriguing hypothesis is that prolonged or intensi®ed activation of GPCRs may be a critical factor tipping the balance between pathways promoting hypertrophic growth and those leading to apoptotic death of cardiomyocytes.
In vitro and in vivo models of cardiomyocyte growth
There are no well-established continuous cell lines that can be used to study cardiomyocyte development and growth. A line of atrial cells (AT-1), immortalized by expression of SV-40 large T-antigen (Delcarpio et al., 1991) has been utilized in electrophysiolgical studies and the HL-1 cardiac muscle cell line has been derived from them (Claycomb et al., 1998) . The availability of these cells is limited, however, and conditions for maintaining their dierentiated properties are stringent. Some investigators have studied embryonic stem cells dierentiated into cardiomyocytes (Minamino et al., 1999) but this preparation is not routinely useful. Myocytes isolated from the ventricle of adult rat, rabbit, and dog heart have been extensively examined to delineate the acute signaling pathways by which GPCRs control cell excitability, calcium and excitation-contraction coupling. However, adult heart cells are generally dicult to maintain in cell culture and substantial changes in their dierentiated properties can occur. Thus adult cardiomyocytes are rarely used to examine control of cell growth.
The vast majority of work carried out over the last 2 ± 3 decades has utilized primary cultures of neonatal rat ventricular myocytes (NRVM) to map the signaling molecules and pathways involved in hypertrophic cardiomyocyte growth. Since little cell division occurs postnatally in cardiac myocytes, increased cardiac mass is achieved primarily through increases in cardiomyocyte cell volume. Hypertrophic growth of myocytes is accompanied by increases in protein synthesis and organization of contractile proteins, such as myosin light chain-2 (MLC-2) into sarcomeric units. In addition, fetal isoforms of various genes including bmyosin heavy chain (MHC) and atrial natriuretic factor (ANF) are re-expressed by hypertrophied myocytes (Parker et al., 1990) .
The initial paradigm demonstrating that neurohormones could increase cardiomyocyte size and their capacity for protein synthesis documented hypertrophy of cultured NRVM in response to norepinephrine (NE) treatment (Simpson et al., 1982; Simpson, 1983) . Using variations of this model, others have demonstrated that cardiomyocyte hypertrophy occurs in response to stimulation by a variety of G-protein coupled receptor agonists, most of which are listed in Table 1 .
Investigation of the signaling pathways mediating hypertrophic growth of NRVMs was signi®cantly advanced by the recognition that these primary cultured cells could be genetically manipulated. Of critical importance was the observation that transcriptional responses could be assessed using the sensitive luciferase reporter gene, driven by promoters for the genes upregulated in hypertrophy (e.g. ANF, MLC-2). Thus even in the face of the relatively low transfection eciency obtained using CaPO 4 or electroporation of NRVMs, genes encoding molecules of interest could be transfected into NRVMs and their eects on regulation of hypertrophic responses examined. Proteins, antibodies or cDNAs encoding genes of interest have also been microinjected into NRVMs. While this approach has also provided important information, only responses that can be measured at the single cell level (e.g. increased immunostaining for ANF protein or altered sarcomere organization visualized by staining with phalloidin) can be monitored. Most recently, high eciency gene delivery has been achieved by infection of NRVMs with cDNAs expressed by replication de®cient recombinant adenoviral vectors. Because virtually all of the cells are infected and high-level expression is obtained, biochemical and molecular changes underlying cardiomyocyte hypertrophy and apoptosis can be assessed.
The in vitro NRVM system has many advantages including ease of culture. Importantly, it circumvents the complexity imposed by interactions of individual myocytes with each other, with non-myocytes, with the extracellular matrix and with circulating growth factors. This degree of isolation provides an ideal platform for the discovery of signaling molecules through which the cardiomyocyte responds to extracellular stimuli or intracellularly expressed mediators. On the other hand, the interactions lacking in this in vitro system could play a central role in the in vivo control of cardiomyocyte growth and death. This dimension is provided by studies using transgenic gene expression in the myocardium, and/or deletion of putative signaling molecules by gene knockout. The a-MHC promoter has been commonly used to achieve cardiac speci®c gene expression in transgenic mice. For example, signaling molecules including G-protein coupled receptors, Gprotein alpha subunits, and kinases such as MAP kinases and PKC have been selectively expressed in myocardium by transgenesis. Despite the caveats applicable to transgenic overexpression of signaling molecules, this paradigm has been invaluable for evaluating the physiological function of candidate molecules discovered using the in vitro cell system (see Izumo and Shioi, 1998 for review).
G-protein involvement in cardiomyocyte hypertrophy

Gq-signaling pathways in cardiomyocyte hypertrophy
Most stimuli that induce myocardial hypertrophy in NRVMs activate G-protein coupled receptors that Ang II AT1 Gq (Sadoshima and Izumo, 1993b) ET-1 ET A Gq/Gi (Shubeita et al., 1990; Hilal-Dandan et al., 1992; ET-3 (Tamamori et al., 1996 PGF2a PGF Gq (Adams et al., 1998a) PE a 1 -AdrR Gq (Bishopric et al., 1987; Chien et al., 1991) LPA Edg (2, 4 or 7 ?) Gq/Gi (Goetzl et al., 2000) Thrombin PAR-1 Gq/Gi (Glembotski et al., 1993; Sabri et al., 2000) NE a 1 -AdrR Gq (Simpson et al., 1982) ISO b 1 , b 2 -AdrR Gs (Simpson, 1985) SPC Edg (1 or 3 ?) Gi (Sekiguchi et al., 1999) regulate the heterotrimeric G-protein Gq (see Table  1 ). Gq-coupled receptor agonists shown to induce hypertrophy in NRVM include norepinephrine (NE), angiotensin II (Ang II), endothelin-1 (ET-1), thrombin, lysophosphatidic acid (LPA) and prostaglandin F2a (PGF2a) (Simpson et al., 1982; Sadoshima and Izumo, 1993a; Ito et al., 1991; Glembotski et al., 1993; Goetzl et al., 2000; Adams et al., 1996) . The activated alpha subunit of Gq directly stimulates phospholipase (PLC), catalyzing the hydrolysis of phosphatidylinositol bisphosphate (PIP 2 ). Several lines of evidence indicate that it is the activation of this pathway that is responsible for induction of kinase cascades and transcriptional responses resulting in hypertrophy. Amongst the earliest studies demonstrating a requirement for Gq were those in which a speci®c antibody to the Gq alpha (Gaq) subunit was microinjected into NRVMs and shown to block PE stimulated ANF expression, cell enlargement, and myo®lament organization (LaMorte et al., 1994) ; the same antibody was also demonstrated to block the PE and GTPgS stimulated activation of PLC in these cells. Studies comparing responses to heterologously expressed muscarinic receptor subtypes and chimeras in NRVM also indicated that the ability to couple to Gq was required for activation of hypertrophic signals (Ramirez et al., 1995) . The ability to activate PLC also correlates with the dierential ability of a 1A/C vs a 1B AdrR to induce cardiomyocyte hypertrophic responses. (McWhinney et al., 1999) . Finally recent experiments in our laboratory have demonstrated that overexpression of the alpha subunit of Gq by adenoviral infection of NRVMs results in increased PLC activity and development of a hypertrophic phenotype similar to that caused by activation of Gq-coupled receptors (Adams et al., 1998b (Adams et al., , 2000 . The hypertrophic phenotype, induced by agonist or Gaq expression are evident in Figure 1 , where actin ®laments are stained with¯uorescently-tagged phalloidin in ®xed cells. One of the important second messengers generated when PIP 2 is hydrolyzed by PLC is Ins (1,4,5)P 3 . The production of Ins(1,4,5)P 3 and subsequent release of Ca 2+ from endoplasmic reticular stores plays a critical role in Gq-induced signaling in most systems. Interestingly it is not clear that signi®cant Ins(1,4,5)P 3 formation occurs in response to the G-protein activation in NRVMs (Matkovich and Woodcock, 2000) or that Ins(1,4,5)P 3 induced Ca 2+ release is of major physiological signi®cance in the heart. The other product of PLC induced cleavage of PIP 2 , diacylglycerol, likely plays a key role in hypertrophic responses by regulating the activity of protein kinase C (PKC). The role of PKC as a growth signaling molecule in the myocyte has been demonstrated by studies examining the eects of phorbol esters (Dunnmon et al., 1990) , by overexpression of constitutively activated forms of PKC in NRVMs (Shubeita et al., 1992; Kariya et al., 1991; Takeishi et al., 2000) , by studies using pharmacological inhibitors (Komuro et al., 1991; Karns et al., 1995; Yamazaki et al., 1995 Yamazaki et al., , 1999 and in experiments with receptors for activated C-kinases (RACKS) (Mochly-Rosen et al., 2000) . The role of PKC in cardiac growth regulation is the subject of extensive investigation and numerous critical reviews (Steinberg et al., 1995; Puceat and Vassort, 1996; Simpson, 1999; Jalili et al., 1999) . MAP Kinases are also activated in response to the Gq coupled receptor agonists. Their role in hypertrophic cell growth is well documented, albeit not always conclusive (see Sugden and Clerk, 1998 for review).
Gq-coupled receptors in cardiac hypertrophy
Most forms of cardiovascular stress that lead to cardiac hypertrophy activate the sympathetic nervous system and elevate plasma NE levels. This observation, coupled with the in vitro eects of NE, suggest a causal relationship between adrenergic receptor activation and cardiac hypertrophy in the intact heart. Hypertrophic eects of NE appear to occur predominantly through a 1 -adrenergic receptor (a 1 -AdrR) activation. The a 1 -AdrR subtypes that regulate cardiomyocyte function are the a 1A/C and a 1B (for review see Varma and Deng 2000) . One of the earliest studies using cardiac speci®c gene expression in transgenic mice showed that an activated mutant of the a 1B -AdrR, expressed in the mouse ventricle, resulted in mild cardiac hypertrophy (Milano et al., 1994a) . No hypertrophy developed in transgenic mice expressing wild type a 1B -AdrR (Akhter et al., 1997; Grupp et al., 1998) . This may re¯ect the weak coupling of the a 1B -AdrR to PLC (Theroux et al., 1996) . Viral expression of the a 1B receptor also fails to stimulate PLC or hypertrophy in NRVMs. In contrast, the a 1A/C receptor stimulates both inositol phosphate production and ANF-luciferase expression (McWhinney et al., 1999) . Studies using pharmacological inhibitors to block PE induced hypertrophy and phosphoinositide hydrolysis in NRVM also support the notion that the a 1A/C -AdrRs, signaling through Gq to PLC, that mediates the hypertrophic response to catecholamines, at least in the rat heart Knowlton et al., 1993) . Transgenic mice in which the a 1A/C receptor is overexpressed and mice in which the a 1A/C receptor is knocked out have been generated, however no data on development of hypertrophy in these animals is yet published.
It is now well established that ACE inhibitors, which block Ang II formation, prevent the development of pressure overload induced cardiac hypertrophy in animal models and in humans (Zhu et al., 1997) . However, ACE inhibition aects other aspects of cardiovascular regulation including sympathetic tone. There is also evidence for attenuation of experimentally induced cardiac hypertrophy by receptor antagonists to Ang II. The salutary eects of AT1 receptor blockers have been demonstrated to occur independently of the drugs eects on blood pressure (Linz and Scholkens, 1992; Ehmke et al., 1999) . Studies using the AT1 antagonists losartan and valsartan demonstrate a role of AT1 receptors in hypertrophic growth, both in vitro and in vivo (Sadoshima and Izumo, 1993b; Thurmann et al., 1998) . However, in vitro studies suggest that a major component of the observed hypertrophy induced by Ang II results from activation of AT1 receptors on non-muscle cells, release of paracrine factors, and activation of growth pathways in neighboring myocytes (Ito et al., 1993) . Interestingly, transgenic mice overexpressing AT1 receptors in the myocardium develop cardiac hypertrophy (Paradis et al., 2000) , but pressure overload and stretch induced hypertrophy still occur in AT1 knockout mice Harada et al., 1998) . Thus, the precise role of Ang II system in regulating cardiac growth remains uncertain.
Other Gq-coupled receptor agonists, including ET-1 and PGF2a likely regulate cardiac hypertrophy in vivo. It is known that endothelin receptor blockers inhibit cardiac hypertrophy induced by hypertension and pressure overload and these agents have been used successfully in animal models of heart failure (Miyauchi and Goto, 1999) . Thus probably this G-protein coupled receptor agonist contributes to the development of cardiac hypertrophy in vivo. PGF2a is an exceedingly eective stimulus for cardiomyocyte hypertrophy in NRVMs (Adams et al., 1996; Lai et al., 1996) . Notably, PGF2a is upregulated in the stressed myocardium (Lai et al., 1996) suggesting that it may also participate in the autocrine/paracrine growth signaling response that underlie hypertrophy in the challenged heart. However, PGF2a receptor knockouts have not been analysed for cardiac responses and antagonists to PGF2a receptors have not been generated, thus the role of PGF2a in in vivo hypertrophy remains to be determined.
Evidence for Gaq signaling in hypertrophic responses of transgenic mice
As discussed above a variety of GPCRs including the a 1 -Adr, Ang II, PGF2a and ET1 receptors participate in the regulation of cardiac growth in NRVMs by coupling to Gaq. To determine whether Gaq activation is sucient to induce hypertrophy in vivo, transgenic mice overexpressing Gaq in the myocardium were generated (D'Angelo et al., 1997). These mice developed cardiac hypertrophy in proportion to the extent of Gaq expression, as demonstrated by increases in cardiac mass, changes in left ventricular function and alterations in hypertrophic gene expression. Evidence that Gaq is sucient to induce hypertrophy in transgenic mice was complemented by several lines of evidence indicating that Gaq activation was necessary for hypertrophy in response to pressure overload induced by transverse aortic constriction. In one study, a Gaq inhibitor peptide previously shown to prevent receptor coupling to Gaq was expressed in the myocardium of transgenic mice (Akhter et al., 1998) . Hypertrophy induced by pressure overload was signi®cantly attenuated in these animals. A separate line of evidence for the involvement of Gaq signaling derived from studies using transgenic expression of RGS4, which acts as a GTPase activator protein (GAP) for, and attenuates activation of, Gaq. When expressed in the mouse heart, RGS4 signi®cantly diminished pressure overload induced hypertrophy (Rogers et al., 1999) . Finally, recent studies demonstrate complete absence of a hypertrophic response to pressure overload in cardiac-restricted Gaq/Ga 11 knockout mice (S Oermanns, personal communication). Taken together, these results support the hypothesis that Gaqmediated signaling is both necessary and sucient for the development of cardiac hypertrophy.
Gs signaling in cardiac hypertrophy
The b-Adr receptors are powerful regulators of cardiac contractile function. Stimulation of b-Adr receptors increases heart rate and myocardial contractility by coupling to the heterotrimeric G-protein Gas, which, upon activation, stimulates adenylyl cyclase resulting in the formation of cAMP. Activation of the cAMP dependent protein kinase (PKA) induces the phosphorylation of L-type Ca 2+ channels (increasing Ca 2+ entry at each beat), of phospholamban (increasing the uptake of Ca 2+ into the sarcoplasmic reticulum), of troponin I (increasing the cross-bridge cycling rate), and of the ryanodine receptor (gating Ca 2+ release from the SR). Because the Gas-cAMP signaling pathway is rapidly activated and inactivated, it is well suited for instantaneous control of cardiovascular performance in response to demand.
Early studies suggested that cardiac hypertrophy, induced by chronic NE infusion, was attenuated by treatment with b-AdrR antagonists (Zierhut and Zimmer, 1989) . Similarly, studies in Simpson's laboratory demonstrated a modest hypertrophic eect of the b-adrenergic agonist, isoproterenol, in NRVMs (Simpson, 1985) . This growth response was suggested to be dependent upon increased myocyte contractile activity, and due at least in part to the release of paracrine factors by non-muscle cells (for review see Long et al., 1992) . Recently, transgenic mice overexpressing Gas in the myocardium have been generated and extensively studied (Vatner et al., 2000; Iwase et al., 1996 Iwase et al., , 1997 . As expected, an increase in contractile sensitivity to badrenergic stimulation was evident. Interestingly analysis of Gas transgenic mice expressing the transgene in a chimeric fashion indicated that hypertrophy was not evenly distributed among the Gas expressing cells but was prominent in regions where Gas expressing cells were concentrated and lacking in regions where Gas expressing cells were sparse (Vatner et al., 2000) . This suggested that local areas of enhanced contraction or neurohumoral signaling were involved in the development of the hypertrophic phenotype. The ®ndings from this in vivo model of Gas overexpression are consistent with the in vitro data suggesting that b-AdrR/G s induced hypertrophy may occur as a secondary response to the well known contractile eects mediated via Gas signaling.
The b 1 -AdrR is the predominant cardiac subtype. b 1 -AdrR transgenic mice exhibit cardiomyocyte hypertrophy and increased contractile function (Engelhardt et al., 1999; Bisognano et al., 2000) . In these mice, hypertrophy progressed to a dilated cardiomyopathy with loss of ventricular function, myocyte degeneration and replacement ®brosis (Bisognano et al., 2000; Engelhardt et al., 1999) . In contrast to the striking eects observed in b 1 -AdrR transgenics b 2 -AdrR expression lead to enhanced contractile function without signi®cant cardiomyocyte hypertrophy or pathophysiology, except at extraordinarily high levels of receptor expression (Milano et al., 1994b; Rockman et al., 1996; Liggett et al., 2000) . These data indicate that b 2 -AdrR eects on cardiomyocyte contractile functions do not necessarily lead to cardiomyocyte hypertrophy. Dierences in b 2 -and b 1 -AdrR signaling pathways discussed below may account for these dierences.
Gi signaling pathways in cardiac hypertrophy
There is limited evidence supporting a role for G i signaling in cardiomyocyte hypertrophy. Some growth factors that stimulate hypertrophy through receptors coupled to Gq also induce receptor coupling to G i (see Table 1 ). G i activation can contribute to the hypertrophic response to these agonists. For example, inhibition of G i signaling with pertussis toxin partially inhibits ET-1 stimulated hypertrophy in cultured neonatal rat ventricular myocytes (Hilal-Dandan et al., 1997) . Similarly, sphingosylphosphorylcholine (SPC) induced cardiomyocyte hypertrophy is attenuated by pertussis toxin treatment (Sekiguchi et al., 1999) . The notion that G i signaling alone is not sucient for cardiomyocyte hypertrophy is consistent with the ®nding that G i linked M 2 muscarinic cholinergic receptors did not induce hypertrophy whereas a chimeric M 2 muscarinic receptor that coupled to Gq was eective in this regard (Ramirez et al., 1995) .
It is known that G i signaling pathways regulate activation of the ERK family of MAP kinases. This occurs through eects of released bg subunits on PI3 kinase and/or bARK, with subsequent activation of downstream kinase cascades (Src, Ras, Raf-1). Notably, ERK MAP kinase activation itself is unlikely to be a sucient stimulus for induction of hypertrophic cardiomyocyte growth (Post et al., 1996) . In addition, there is little evidence for a critical role for bg signaling in cardiac hypertrophy. While bg subunits released from Gq were shown to be responsible for PI3 kinase activation in response to banding (Prasad et al., 2000) , mice expressing the bARK C-terminal domain, which binds to and blocks the function of bg subunits, had a normal hypertrophic response to pressure overload (Choi et al., 1997) .
We recently observed that an activated mutant form of Ga i2 when overexpressed via adenoviral infection is sucient to induce hypertrophic growth of NRVMs (Meszaros et al., manuscript in preparation). This could re¯ect more promiscuous coupling of the highly expressed Ga subunit to a tyrosine kinase pathway. It is perhaps noteworthy that the eectiveness of G i pathways in regulating hypertrophy may be greater in neonatal cardiomyocytes isolated from mouse (vs rat) ventricle. These cells show surprisingly poor induction of hypertrophy by exogenous ligands, but undergo spontaneous hypertrophy in culture, through a pertussis toxin sensitive pathway (Deng et al., 2000 and P Simpson, personal communication) .
G-protein involvement in cardiomyocyte apoptosis and heart failure Cellular growth is characterized by up-regulation of genes and transcription factors that promote cell-cycle progression. Since mature cardiac myocytes cannot divide, it has been suggested that stimuli that promote cardiomyocyte growth may ultimately lead to apoptosis instead of cell division (Katz, 1995) . This paradigm was apparent in studies in which forced overexpression of the transcription factor E2F-1 led not only to DNA synthesis, but also to widespread apoptosis (Agah et al., 1997) of cardiac myocytes. Therefore, although hypertrophy may serve as a short-term adaptive process to increase the contractile mass of the heart, the growth signals responsible for hypertrophic growth may eventually lead to cardiomyocyte apoptosis. Cardiomyocyte apoptosis has been associated with heart failure in several animal models including pressure overload, myocardial infarction, and hypertrophic and idiopathic dilated cardiomyopathies. A causal link between apoptotic myocyte death and the transition from compensatory hypertrophy to cardiac dysfunction and failure is rapidly gaining acceptance.
Studies using isolated cells or transgenic animals in which GPCR signaling pathways are highly activated suggest that G-protein signaling can cause cardiomyocyte apoptosis. This would provide a plausible pathogenic link between elevated levels of neurohormones that activate G-protein coupled receptors, the altered expression of G-proteins and their eectors, and the development of overt heart failure. Signi®-cantly, if cardiomyocyte apoptosis contributes to loss of contractile cells and to cardiac failure in the pathologically stressed heart, interventions limiting Gprotein signaling should be eective strategies for preventing these pathophysiological events.
Gaq signaling in apoptosis and failure
One of the ®rst lines of evidence for the involvement of Gq signaling in cardiomyocyte apoptosis came from experiments carried out in Anversa's laboratory. In these studies Ang II was demonstrated to induce apoptosis in neonatal and adult myocytes via PKC and calcium dependent pathways Cigola et al., 1997) . The AT1 receptor antagonist losartan blocked Ang II-induced apoptosis, while an AT2 receptor blocker was ineective. Interestingly, losartan also blocked stretch-induced apoptosis in cultured adult cardiomyocytes (Leri et al., 1998) suggesting that the Gq-coupled AT1 receptor mediates activation of apoptotic pathways by mechanical stretch. Several studies have shown that ACE inhibitors or AT receptor antagonists also block the cardiomyocyte apoptosis observed in spontaneously hypertensive rats Goussev et al., 1998; FortunÄ o et al., 1998) .
While the initial hypertrophic response to Gqcoupled receptor stimulation in the stressed heart is adaptive, we have demonstrated that prolonged activation of these pathways may become maladaptive as a result of cumulative loss of myocytes through apoptosis (Adams et al., 1998b; Dorn and Brown, 1999) . Direct evidence for the activation of apoptotic pathways by Gq signaling derives from in vitro studies using recombinant adenovirus to express a constitutively activated mutant form of the alpha subunit of Gq (GaqQ209L). These studies showed that sustained activation of Gaq and concomitant stimulation of PLC induced marked apoptosis of cultured neonatal rat ventricular myocytes (Adams et al., 1998b) . More recently we demonstrated that addition of Gq-coupled receptor agonists (PGF2a or PE) to hypertrophied cardiomyocytes overexpressing wild type Gaq caused robust PLC activation, comparable to that seen with expression of GaqQ209L, and likewise induced apoptosis (Adams et al., 2000) . These paradigms were recapitulated in transgenic mice generated in Dorn's laboratory. Initial studies with these transgenic mice showed that a modest (four-fold) overexpression of Gaq in the myocardium lead to development of a stable form of cardiac hypertrophy (D'Angelo et al., 1997) . However, when these mice were subjected to the neurohumoral or hemodynamic stresses associated with parturition (Adams et al., 1998b) or to chronic pressure overload Adams et al., manuscript in preparation) cardiac failure rapidly developed in association with increased cardiomyocyte apoptosis. Another line of transgenic mice expressing an activated rather than wild type form of Gaq in the myocardium rapidly developed marked hypertrophy and a dilated cardiomyopathy (Mende et al., 1998) . Preliminary studies provide evidence for marked apoptosis in the hearts of these animals (U Mende and J Adams, in preparation). The pathways responsible for Gaq induced apoptosis are under investigation. One pathway that has been implicated is the activation of the stress-activated kinases, p38 and JNK, which are enhanced in cells undergoing Gaq-induced apoptosis (Adams et al., 1998b) . In addition, mitochondrial permeability is increased in GaqQ209L expressing cells which represents a critical target for rescue of Gaq induced apoptosis (Adams et al., 2000) .
Gas signaling in apoptosis and failure
A number of studies have documented that catecholamines are elevated in the plasma of heart failure patients (Hasking et al., 1986 ). An association between activation of the sympathetic nervous system, elevation of circulating catecholamines, and the development of heart failure is well documented. Chronically elevated levels of Gas signaling, as would be imposed by increased catecholamines, leads to a gradual decrease in responsiveness (desensitization) to inotropic stimulation by b-AdrR agonists. The mechanisms involved in b-AdrR desensitization include a decrease in b 1 -AdrR receptor number, an uncoupling of the b-AdrR from Gas, an increase in Gai, a decrease in adenylyl cyclase activity, and an increase in the receptor kinase, (bARK), which phosphorylates and down-regulates the b-AdrR. The global loss in b-AdrR sensitivity imposed at these various levels was thought for many years to be the cause of cardiac failure. On the other hand, the down regulation of the b-AdrR pathway could be viewed as an adaptation to, rather than a cause of, heart failure. In this regard, ameliorative eects of beta (b-AdrR) blockers in animal models of heart failure and in clinical trials with heart failure patients are now well documented (for review see Sabbah, 1999) . The possibility that excessive b-AdrR signaling predisposes to heart failure provides a new focal point for studying the role of b-AdrR signaling in models of heart failure.
NE was shown to induce apoptosis in isolated adult rat ventricular cardiomyocytes, through stimulation of the b-AdrR (Communal et al., 1998) . In a subsequent study apoptosis was shown to be mediated through the b 1 -AdrR, via eects on cyclic AMP (Communal et al., 1999) . Zaugg et al. (2000) also demonstrated that it is the b 1 -AdrR which mediates the apoptotic response to NE. This ®nding is particularly relevant in light of the observation that transgenic animals expressing b 1 -AdrR, even at relatively low levels, develop heart failure associated with apoptosis (Engelhardt et al., 1999; Bisognano et al., 2000) . The notion that increased G s signaling can lead to apoptosis is further supported by studies demonstrating that heart failure and apoptosis develop in older transgenic mice overexpressing the alpha subunit of G s in the myocardium . When activation of endogenous b-AdrR in Gas transgenic mice was blocked with propranolol, cardiomyocyte apoptosis and cardiac dysfunction were prevented (Akai et al., 1999) . These studies suggest that chronic sympathetic stimulation over an extended period of time can contribute to the development of apoptotic heart failure.
In contrast to what is observed for b 1 -AdrR or G s overepression, b 2 AdrR expression results in the development of cardiomyopathy only when receptor levels are extremely high (Liggett et al., 2000) . It has been suggested that the b 2 7-AdrR couples not only to G s but also to G i . The b 2 -AdrR has been shown to functionally antagonize b 1 -AdrR responses through a PTX-sensitive pathway (Xiao et al., 1995) . Likewise, b 2 -AdrR coupling to a PTX sensitive protein (presumably G i ) also acts to suppress apoptotic responses to b-AdrR stimulation (Communal et al., 1999) or to ischemic stress (Chesley et al., 2000) . These data suggest that activation of b 2 -AdrR could serve an important function by limiting the apoptotic response to, and development of heart failure following ischemia or prolonged b-AdrR stimulation.
The mechanism of b 1 -AdrR induced apoptosis is under investigation. A pathway requiring protein kinase A was implicated in the apoptosis induced by chronic infusion of isoproterenol in vivo (Shizukuda et al., 1998) . In other studies isoproterenol-induced cardiomyocyte apoptosis was demonstrated to be mediated by a calcium-calcineurin pathway (Saito et al., 2000) . Thus, cyclic AMP and Ca 2+ would appear to be second messengers in these pathways. Interestingly, the inhibitory eect of b 2 -AdrR and Gi signaling does not appear to be mediated by decreasing cyclic AMP but instead via p38 MAP kinase or PI3 kinase (Chesley et al., 2000) .
Ga i signaling in cardiac apoptosis and failure
Increased expression of Ga i protein (speci®cally Ga i2 ) is observed in models of dilated cardiomyopathy (Bohm et al., 1990 (Bohm et al., , 1994 . Cardiomyocytes isolated from failing hearts show depressed inotropic responses to isoproterenol, which can be restored by inactivating G i with pertussis toxin (Brown and Harding, 1992) . These ®ndings suggested a causal relationship between increased Ga i expression and the decreased contractile function associated with heart failure. More recently Conklin's group demonstrated that myocardial expression of a conditionally activated Ga i -linked receptor resulted not only in decreased heart rate and contractility but in development of a lethal dilated cardiomyopathy (Redman et al., 2000) , mirroring the physiological response associated with increased G i expression. There is no data indicating that increased G i expression causes heart failure through induction of apoptosis. In fact, as discussed above, increased G i expression might be expected to decrease apoptotic signaling, e.g. via protective eects of G i signaling on activation of p38 kinase or PI3 kinase. Thus, while changes in Ga 1 function can clearly aect both hypertrophic and apoptotic responses, the role of G i signaling in cardiomyocyte growth appears at present to be largely modulatory.
Abbreviations a-AR, a-AdrR: a-adrenergic receptor; b-AR, b-AdrR: badrenergic receptor; b-ARK; b-adrenergic receptor kinase; a-MHC, b-MHC: a-myosin heavy chain, b-myosin heavy chain; ACE: angiotensin-converting enzyme; ANF: atrial natriuretic factor; Ang II: angiotensin II; cAMP: cyclic AMP; ET-1: endothelin-1; GAP: GTPase activator protein; GPCR: G protein-coupled receptor; ISO: isoproterenol; LPA: lysophosphatidic acid; MAP kinase: mitogen-activated protein kinase; MLC-2: myosin light chain-2; NE: norepinephrine; NRVM: neonatal rat ventricular myocyte; PAR: protein-activated receptor; PE: phenylephrine; PGF2a: prostaglandin F2a; PIP 2 : phosphatidylinositol bisphosphate; PKA: cAMP-dependent protein kinase; PKC: protein kinase C; PLC: phospholipase C; RACKS: receptors for activated C-kinases; RGS4: regulator of G protein signaling 4; SPC: sphingosylphosphorylcholine.
